Abstract
Fatigue is common in Parkinson’s disease (PD), occurring in up to 42% of patients (2). There is no recognized treatment. This is a study of modafinil for Parkinson’s disease related fatigue. Ethical approval was given. Patients with idiopathic PD were recruited from a Movement Disorders clinic. Those with depression, dementia, and other causes for fatigue were excluded. Patients were assessed using the Fatigue Severity Scale (FSS), Hospital Anxiety and Depression Scale (HADS), self-rating of improvement, Epworth Sleepiness Scale (ESS), and UPDRS. Modafinil was titrated up over 4 weeks to maximum of 400 mg/day. There followed a 5 week maintenance phase before reassessment. Thirteen patients participated. No significant change was seen in any safety measure. The FSS did not change significantly, however those on modafinil rated an improvement in their fatigue compared to placebo. The Modafinil group had a statistically significant improvement on ESS (p < 0.05). This is a small study of modafinil in selected PD patients. There is a suggestion of improvement on the global clinical impression scale for fatigue, but no significant change on FSS. A larger study is needed to further evaluate this drug in PD fatigue. This study highlights the problems with recruitment when trialing treatments of non-motor symptoms in PD. A significant improvement in EDS was seen.
Similar content being viewed by others
References
Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD (1989) The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46(10):1121–1123
Karlsen KH, Larsen JP, Tandberg E, Maeland JG (1999) Influence of clinical and demographic variables on quality of life in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 66(4):431–435
Friedman J, Friedman H (1993) Fatigue in Parkinson’s disease. Neurology 43(10):2016–2018
Mendonca DA, Menezes K, Jog MS (2007) Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial. Mov Disord 22(14):2070–2076
Beusterien KM, Rogers AE, Walsleben JA, Emsellem HA, Reblando JA, Wang L et al (1999) Health-related quality of life effects of modafinil for treatment of narcolepsy. Sleep 22(6):757–765
Zifko UA, Rupp M, Schwarz S, Zipko HT, Maida EM (2002) Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. J Neurol 249(8):983–987
Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja HN (2002) Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry 72(2):179–183
Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J (2003) Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson’s disease. Mov Disord 18(3):287–293
Herlofson K, Larsen JP (2002) Measuring fatigue in patients with Parkinson’s disease–the Fatigue Severity Scale. Eur J Neurol 9(6):595–600
Ondo WG, Dat VK, Khan H, Atassi F, Kwak C, Jankovic J (2001) Daytime sleepiness and other sleep disorders in Parkinson’s disease. Neurology 57(8):1392–1396
Alves G, Wentzel-Larsen T, Larsen JP (2004) Is fatigue an independent and persistent symptom in patients with Parkinson disease? Neurology 63(10):1908–1911
Brown RG, Dittner A, Findley L, Wessely SC (2005) The Parkinson fatigue scale. Parkinsonism Relat Disord 11(1):49–55
Havlikova E, van Dijk JP, Rosenberger J, Nagyova I, Middel B, Dubayova T, Gdovinova Z, Groothohh JW (2008) Fatigue in Parkinson’s disease is not related to excessive sleepiness or quality of sleep. J Neurol Sci 270:107–113
Acknowledgment
Cephalon UK gave an unrestricted educational grant. However, they were not involved in the trial, its procedure, or in assessing the outcome.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tyne, H.L., Taylor, J., Baker, G.A. et al. Modafinil for Parkinson’s disease fatigue. J Neurol 257, 452–456 (2010). https://doi.org/10.1007/s00415-009-5351-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-009-5351-8